Patents by Inventor Karl Clauser

Karl Clauser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220088180
    Abstract: Immunogenic compositions comprising one or more polypeptides, wherein the one or more polypeptides: is capable of binding to Major Histocompatibility Complex (MHC) class I, and is derived from one or more proteins of SARS-CoV-2. Also provided include methods of treating and preventing diseases using the immunogenic compositions.
    Type: Application
    Filed: August 31, 2021
    Publication date: March 24, 2022
    Inventors: Pardis SABETI, Shira Weingarten-Gabbay, Susan Klaeger, Jenn Abelin, Mohsan Saeed, Nir Hacohen, Siranush Sarkizova, Steven Carr, Karl Clauser
  • Publication number: 20220062394
    Abstract: Disclosed herein are polypeptides and compositions comprising one or more neoantigens, methods of identifying neoantigens, and methods for preparing a neoantigen for an immunogenic pharmaceutical composition. The neoantigen can be specific to a subject that has a cancer, disease, or other disorder.
    Type: Application
    Filed: December 12, 2019
    Publication date: March 3, 2022
    Inventors: Tamara Ouspenskaia, Travis Law, Aviv Regev, Steven Carr, Karl Clauser, Susan Klaeger, Nir Haochen, Catherine J. Wu, Derin Keskin
  • Publication number: 20210382068
    Abstract: Adaptive immune responses rely on the ability of cytotoxic T cells to identify and eliminate cells displaying disease-specific antigens on human leukocyte antigen (HLA) class I molecules. Investigations into antigen processing and display have immense implications in human health, disease and therapy. To extend understanding of the rules governing antigen processing and presentation, immunopurified peptides from B cells, each expressing a single HLA class I allele, were profiled. A resource dataset containing thousands of peptides bound to distinct class I HLA-A, -B, and -C alleles was generated by implementing a novel allele-specific database search strategy. Applicants discovered new binding motifs, established the role of gene expression in peptide presentation and improved prediction of HLA-peptide binding by using these data to train machine-learning models. These streamlined experimental and analytic workflows enable direct identification and analysis of endogenously processed and presented antigens.
    Type: Application
    Filed: October 2, 2019
    Publication date: December 9, 2021
    Inventors: Derin Keskin, Siranush Sarkizova, Susan Klaeger, Karl Clauser, Steven Carr, Nir Hacohen, Catherine J. Wu
  • Patent number: 10024860
    Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyzes of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: July 17, 2018
    Assignees: Massachusetts Institute of Technology, The General Hospital Corporation, The Broad Institute, Inc.
    Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
  • Publication number: 20170343553
    Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.
    Type: Application
    Filed: September 22, 2016
    Publication date: November 30, 2017
    Applicants: Massachusetts Institute of Technology, The General Hospital Corporation d/b/a Massachusettes General Hospital, The Broad Institute, Inc.
    Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
  • Publication number: 20170051073
    Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.
    Type: Application
    Filed: September 22, 2016
    Publication date: February 23, 2017
    Applicants: Massachusetts Institute of Technology, The General Hospital Corporation d/b/a Massachusettes General Hospital, The Broad Institute, Inc.
    Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
  • Patent number: 9526800
    Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyzes of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: December 27, 2016
    Assignees: Massachusetts Institute of Technology, The General Hospital Corporation, The Broad Institute, Inc.
    Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
  • Publication number: 20150086565
    Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 26, 2015
    Applicants: Massachusetts Institute of Technology, The General Hospital Corporaiton d/b/a Massachusetts General Hospital, The Broad Institute, Inc.
    Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe